BD1 | Jotup

Teleflex Launches New Arrow® VPS Rhythm® DLX Device and NaviCurve™ Stylet in the United States

Retrieved on:

Tuesday, May 2, 2023

BD1, Inferior vena cava, Anatomy, Catheter, TFX, Research, PICC, Hospital, VPS, SVC, NYSE, CHG, Medical device, Medical imaging, Teleflex

The new Arrow® VPS Rhythm® DLX Device and NaviCurve™ Stylet are engineered to work together to give Vascular Access Specialists more efficient and predictable PICC placement.

Key Points:

The new Arrow® VPS Rhythm® DLX Device and NaviCurve™ Stylet are engineered to work together to give Vascular Access Specialists more efficient and predictable PICC placement.
The next-generation VPS Rhythm® DLX Device provides real-time catheter tip location information by using the patient’s cardiac electrical activity.
The device is also available with an optional integrated ultrasound featuring a Catheter-to-Vessel ratio tool that promotes standardization in vessel measurement.
This device works in concert with the Arrow® PICC preloaded with the NaviCurve™ Stylet, providing innovative tip navigation/location technologies.

VYNE Therapeutics Announces Selection of Development Candidate VYN202, a Potential Best-in-Class Oral Small Molecule BD2-Selective BET Inhibitor for the Treatment of Immuno-Inflammatory Conditions

Retrieved on:

Monday, May 1, 2023

Research, H4, BET, H3, Attention deficit hyperactivity disorder predominantly inattentive, BD2, BD1, Therapy, Thrombocytopenia, Gene, Safety, Tay, Pharmaceutical industry, IND

BRIDGEWATER, N.J., May 01, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced the selection of a development candidate for its oral BD2-selective bromodomain and extra-terminal (“BET”) inhibitor program, VYN202, for the treatment of immuno-inflammatory conditions. The lead candidate was selected by VYNE from a library of BD2-selective BET inhibitors that VYNE exclusively licensed from Tay Therapeutics following the receipt of a robust package of preclinical data, including encouraging results from well-validated animal models in various autoimmune disorders. VYNE also obtained rights to several other BD2-selective BET inhibitor compounds with attractive molecular profiles that the Company may develop, at its discretion, in the future.

Key Points:

BRIDGEWATER, N.J., May 01, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced the selection of a development candidate for its oral BD2-selective bromodomain and extra-terminal (“BET”) inhibitor program, VYN202, for the treatment of immuno-inflammatory conditions.
The lead candidate was selected by VYNE from a library of BD2-selective BET inhibitors that VYNE exclusively licensed from Tay Therapeutics following the receipt of a robust package of preclinical data, including encouraging results from well-validated animal models in various autoimmune disorders.
VYNE also obtained rights to several other BD2-selective BET inhibitor compounds with attractive molecular profiles that the Company may develop, at its discretion, in the future.
As epigenetic readers, BET proteins are super-enhancers of gene transcription that drive the hyperactive production of many pro-inflammatory proteins that characterize autoimmune and autoinflammatory diseases.

VYNE Therapeutics Announces Positive First-In-Human Pharmacokinetic and Hematology Data from Phase 1a Single and Multiple Ascending Dose Trial for Novel Pan-Bromodomain BET Inhibitor VYN201

Retrieved on:

Thursday, March 30, 2023

Plasma, BET, BD1, Therapy, EC50, BRD4, Patient, Thrombocytopenia, Safety, Hematology, Pharmaceutical industry

BRIDGEWATER, N.J., March 30, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced positive first-in-human pharmacokinetic and hematology data from its Phase 1a single and multiple ascending dose trial for its investigational novel BET inhibitor, VYN201.

Key Points:

BRIDGEWATER, N.J., March 30, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced positive first-in-human pharmacokinetic and hematology data from its Phase 1a single and multiple ascending dose trial for its investigational novel BET inhibitor, VYN201.
In February 2023, the Company announced positive preliminary safety and tolerability data from the trial.
The Phase 1a portion of the trial included comprehensive pharmacokinetic sampling to ascertain the exposure to topically-applied VYN201 from single and repeat treatment of VYN201 over five ascending dose cohorts.
Results have shown that there were no quantifiable VYN201 plasma concentrations above the assay lower limit of quantification (0.25ng/ml).

VYNE Therapeutics Reports Year-End 2022 Financial Results and Provides Business Update

Retrieved on:

Thursday, March 9, 2023

School of Life Sciences (University of Dundee), University, BD2, IND, Letter, BD1, Therapy, Patient, FDA, Vitiligo, AD, Disease, Patent, Inflammation, Atopic dermatitis, BET, Pharmaceutical industry

BRIDGEWATER, N.J., March 09, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced financial results for the fourth quarter and year ended December 31, 2022 and provided a business update.

Key Points:

“With only one FDA-approved therapy currently available for this large patient population, vitiligo remains a significant unmet medical need.
Based on these preliminary results, the Company has selected three doses for testing in the Phase 1b portion of the trial.
The patent, exclusively licensed to Tay Therapeutics Ltd. ("Tay") and sublicensed to VYNE, will expire in April 2040.
In February 2023, VYNE and its license partner, Tay, extended the exclusive option agreement for VYN202 to April 30, 2023.

Nuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-868 for the Treatment of Advanced Solid Tumors

Retrieved on:

Thursday, January 20, 2022

With the clearance of this IND for NUV-868 in advanced solid tumors, Nuvation Bio will be initiating a Phase 1/2 study of NUV-868 as a monotherapy and in combination with olaparib or enzalutamide in multiple tumor types.

Key Points:

With the clearance of this IND for NUV-868 in advanced solid tumors, Nuvation Bio will be initiating a Phase 1/2 study of NUV-868 as a monotherapy and in combination with olaparib or enzalutamide in multiple tumor types.
This protocol (NUV-868-01) will begin with a Phase 1 monotherapy dose escalation study in advanced solid tumor patients.
Nuvation Bio anticipates that subsequent events and developments will cause its assessments to change.
However, while Nuvation Bio may elect to update these forward-looking statements at some point in the future, Nuvation Bio specifically disclaims any obligation to do so.